Dinutuximab

Drug Profile

Dinutuximab

Alternative Names: Anti-GD2 monoclonal antibody ch14.18; Ch14.18; ch14.18-UTC; Chimeric anti-GD2 monoclonal antibody; Unituxin

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer National Cancer Institute (USA); St. John of God Foundation; United Therapeutics Corporation
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuroblastoma
  • Phase II/III Small cell lung cancer
  • Discontinued Malignant melanoma

Most Recent Events

  • 04 Aug 2017 Phase-II/III clinical trials in Small cell lung cancer (Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in Lithuania (IV) (EudraCT2017-000758-20)
  • 01 Jun 2017 Phase-II/III clinical trials in Small cell lung cancer (Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03098030)
  • 21 Apr 2017 Phase-II/III clinical trials in Small cell lung cancer (Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in Spain (IV) (EudraCT2017-000758-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top